Fumarate hydratase inhibits non‑small cell lung cancer metastasis via inactivation of AMPK and upregulation of DAB2

Vadhan,Anupama; Yang,Yi-Fang; Wang,Yun-Ming; Chen,Pang-Yu; Tzou,Shey-Cherng; Cheng,Kuang-Hung; Hu,Stephen Chu-Sung; Cheng,Tian-Lu; Wang,Yen-Yun; Yuan,Shyng-Shiou F.

doi:10.3892/ol.2022.13627

Fumarate hydratase inhibits non‑small cell lung cancer metastasis via inactivation of AMPK and upregulation of DAB2

Authors:
- Anupama Vadhan
- Yi-Fang Yang
- Yun-Ming Wang
- Pang-Yu Chen
- Shey-Cherng Tzou
- Kuang-Hung Cheng
- Stephen Chu-Sung Hu
- Tian-Lu Cheng
- Yen-Yun Wang
- Shyng-Shiou F. Yuan
View Affiliations

Affiliations: Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan, R.O.C., Department of Biological Science and Technology, Institute of Molecular Medicine and Bioengineering, Center for Intelligent Drug Systems and Smart Bio‑devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan, R.O.C., Institute of Molecular Medicine and Bioengineering, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan, R.O.C., Institute of Biomedical Sciences, National Sun Yat‑Sen University, Kaohsiung 804, Taiwan, R.O.C., Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
Published online on: December 9, 2022 https://doi.org/10.3892/ol.2022.13627
Article Number: 42
Copyright: © Vadhan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the leading causes of cancer mortality worldwide. As it is often first diagnosed only when cancer metastasis has already occurred, the development of effective biomarkers for the risk prediction of cancer metastasis, followed by stringent monitoring and the early treatment of high‑risk patients, is essential for improving patient survival. Cancer cells exhibit alterations in metabolic pathways that enable them to maintain rapid growth and proliferation, which are quite different from the metabolic pathways of normal cells. Fumarate hydratase (FH, fumarase) is a well‑known tricarboxylic acid cycle enzyme that catalyzes the reversible hydration/dehydration of fumarate to malate. The current study sought to investigate the relationship between FH expression levels and the outcome of patients with lung cancer. FH was knocked down in lung cancer cells using shRNA or overexpressed using a vector, and the effect on migration ability was assessed. Furthermore, the role of AMP‑activated protein kinase (AMPK) phosphorylation and disabled homolog 2 in the underlying mechanism was investigated using an AMPK inhibitor approach. The results showed that in lung cancer tissues, low FH expression was associated with lymph node metastasis, tumor histology and recurrence. In addition, patients with low FH expression exhibited a poor overall survival in comparison with patients having high FH expression. When FH was overexpressed in lung cancer cells, cell migration was reduced with no effect on cell proliferation. Furthermore, the level of phosphorylated (p‑)AMPK, an energy sensor molecule, was upregulated when FH was knocked down in lung cancer cells, and the inhibition of p‑AMPK led to an increase in the expression of disabled homolog 2, a tumor suppressor protein. These findings suggest that FH may serve as an effective biomarker for predicting the prognosis of lung cancer and as a therapeutic mediator.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Akhtar N and Bansal JG: Risk factors of lung cancer in nonsmoker. Curr Probl Cancer. 41:328–339. 2017. View Article : Google Scholar : PubMed/NCBI
3	Ihde DC: Chemotherapy of lung cancer. N Engl J Med. 327:1434–1441. 1992. View Article : Google Scholar : PubMed/NCBI
4	Hoffman PC, Mauer AM and Vokes EE: Lung cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
5	Gou LY, Niu FY, Wu YL and Zhong WZ: Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population. Cancer. 121:3069–3079. 2015. View Article : Google Scholar : PubMed/NCBI
6	King A, Selak MA and Gottlieb E: Succinate dehydrogenase and fumarate hydratase: Linking mitochondrial dysfunction and cancer. Oncogene. 25:4675–4682. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ming Z, Jiang M, Li W, Fan N, Deng W, Zhong Y, Zhang Y, Zhang Q and Yang S: Bioinformatics analysis and expression study of fumarate hydratase in lung cancer. Thoracic Cancer. 5:543–549. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chen T, Wang T, Liang W, Zhao Q, Yu Q, Ma CM, Zhuo L, Guo D, Zheng K, Zhou C, et al: PAK4 phosphorylates fumarase and blocks TGFβ-induced cell growth arrest in lung cancer cells. Cancer Res. 79:1383–1397. 2019. View Article : Google Scholar : PubMed/NCBI
9	Wang H, Dong S, Liu Y, Ma F, Fang J, Zhang W, Shao S, Shen H and Jin J: DAB2 suppresses gastric cancer migration by regulating the Wnt/β-catenin and Hippo-YAP signaling pathways. Transl Cancer Res. 9:1174–1184. 2020. View Article : Google Scholar : PubMed/NCBI
10	Tian X and Zhang Z: miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. IUBMB Life. 70:71–80. 2018. View Article : Google Scholar : PubMed/NCBI
11	Hocevar BA: Loss of disabled-2 expression in pancreatic cancer progression. Sci Rep. 9:75322019. View Article : Google Scholar : PubMed/NCBI
12	Xu HT, Yang LH, Li QC, Liu SL, Liu D, Xie XM and Wang EH: Disabled-2 and Axin are concurrently colocalized and underexpressed in lung cancers. Hum Pathol. 42:1491–1498. 2011. View Article : Google Scholar : PubMed/NCBI
13	Xie XM, Zhang ZY, Yang LH, Yang DL, Tang N, Zhao HY, Xu HT, Li QC and Wang EH: Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers. Int J Oncol. 43:1636–1642. 2013. View Article : Google Scholar : PubMed/NCBI
14	Li C, Chen J, Chen T, Xu Z, Xu C, Ding C, Wang Y, Lei Z, Zhang HT and Zhao J: Aberrant hypermethylation at sites-86 to 226 of DAB2 gene in non-small cell lung cancer. Am J Med Sci. 349:425–431. 2015. View Article : Google Scholar : PubMed/NCBI
15	Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, Suraokar M, Wistuba I, Minna JD and Pertsemlidis A: miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 33:4307–4315. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang L, Huang P, Li Q, Wang D and Xu CX: miR-134-5p promotes stage I lung adenocarcinoma metastasis and chemoresistance by targeting DAB2. Mol Ther Nucleic Acids. 18:627–637. 2019. View Article : Google Scholar : PubMed/NCBI
17	Hardie DG: AMPK-sensing energy while talking to other signaling pathways. Cell Metab. 20:939–952. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kahn BB, Alquier T, Carling D and Hardie DG: AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15–25. 2005. View Article : Google Scholar : PubMed/NCBI
19	Ashrafizadeh M, Mirzaei S, Hushmandi K, Rahmanian V, Zabolian A, Raei M, Farahani MV, Goharrizi MASB, Khan H, Zarrabi A and Samarghandian S: Therapeutic potential of AMPK signaling targeting in lung cancer: Advances, challenges and future prospects. Life Sci. 278:1196492021. View Article : Google Scholar : PubMed/NCBI
20	Tong WH, Sourbier C, Kovtunovych G, Jeong SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, et al: The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell. 20:315–327. 2011. View Article : Google Scholar : PubMed/NCBI
21	Yuan SSF, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ and Lo S: Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer. J Natl Cancer Inst. 104:1485–1502. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang YY, Chen YK, Lo S, Chi TC, Chen YH, Hu SC, Chen YW, Jiang SS, Tsai FY, Liu W, et al: MRE11 promotes oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in a nuclease-independent manner. Oncogene. 40:3510–3532. 2021. View Article : Google Scholar : PubMed/NCBI
23	Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC, Tsai CH, Chiu WC, Chu-Sung Hu S, Lu CW, et al: Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 37:589–600. 2018. View Article : Google Scholar : PubMed/NCBI
24	Huang JY, Wang YY, Lo S, Tseng LM, Chen DR, Wu YC, Hou MF and Yuan SF: Visfatin mediates malignant behaviors through adipose-derived stem cells intermediary in breast cancer. Cancers (Basel). 12:292019. View Article : Google Scholar : PubMed/NCBI
25	Wang YY, Chen HD, Lo S, Chen YK, Huang YC, Hu SC, Hsieh YC, Hung AC, Hou MF and Yuan SF: Visfatin enhances breast cancer progression through CXCL1 induction in tumor-associated macrophages. Cancers (Basel). 12:35262020. View Article : Google Scholar : PubMed/NCBI
26	Udupa S, Nguyen S, Hoang G, Nguyen T, Quinones A, Pham K, Asaka R, Nguyen K, Zhang C, Elgogary A, et al: Upregulation of the glutaminase II pathway contributes to glutamate production upon glutaminase 1 inhibition in pancreatic cancer. Proteomics. 19:18004512019. View Article : Google Scholar : PubMed/NCBI
27	Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ and Di Renzo MF: Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol. 32:3081–3094. 2012. View Article : Google Scholar : PubMed/NCBI
28	Barker KT, Bevan S, Wang R, Lu YJ, Flanagan AM, Bridge JA, Fisher C, Finlayson CJ, Shipley J and Houlston RS: Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br J Cancer. 87:446–448. 2002. View Article : Google Scholar : PubMed/NCBI
29	Kiuru M, Lehtonen R, Arola J, Salovaara R, Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola J, et al: Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62:4554–4557. 2002.PubMed/NCBI
30	Sciacovelli M, Gonçalves E, Johnson TI, Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo SR, Tran MG, et al: Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition. Nature. 537:544–547. 2016. View Article : Google Scholar : PubMed/NCBI
31	Schmidt C, Sciacovelli M and Frezza C: Fumarate hydratase in cancer: A multifaceted tumour suppressor. Semin Cell Dev Biol. 98:15–25. 2020. View Article : Google Scholar : PubMed/NCBI
32	Ge X, Li M, Yin J, Shi Z, Fu Y, Zhao N, Chen H, Meng L, Li X, Hu Z, et al: Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. Mol Cell. 82:1249–1260.e7. 2022. View Article : Google Scholar : PubMed/NCBI
33	Johnson TI, Costa AS, Ferguson AN and Frezza C: Fumarate hydratase loss promotes mitotic entry in the presence of DNA damage after ionising radiation. Cell Death Dis. 9:9132018. View Article : Google Scholar : PubMed/NCBI
34	Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et al: HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. Cancer Cell. 8:143–153. 2005. View Article : Google Scholar : PubMed/NCBI
35	Sullivan LB, Martinez-Garcia E, Nguyen H, Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ and Chandel NS: The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell. 51:236–248. 2013. View Article : Google Scholar : PubMed/NCBI
36	Gonçalves E, Sciacovelli M, Costa ASH, Tran MGB, Johnson TI, Machado D, Frezza C and Saez-Rodriguez J: Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells. Metab Eng. 45:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
37	Chang YJ, Huang JY, Lin CH and Wang BY: Survival and treatment of lung cancer in Taiwan between 2010 and 2016. J Clin Med. 10:46752021. View Article : Google Scholar : PubMed/NCBI
38	Wang BY, Huang JY, Cheng CY, Lin CH, Ko J and Liaw YP: Lung cancer and prognosis in Taiwan: A population-based cancer registry. J Thorac Oncol. 8:1128–1135. 2013. View Article : Google Scholar : PubMed/NCBI
39	Sciacovelli M and Frezza C: Fumarate drives EMT in renal cancer. Cell Death Differ. 24:1–2. 2017. View Article : Google Scholar : PubMed/NCBI
40	Hou C, Ishi Y, Motegi H, Okamoto M, Ou Y, Chen J and Yamaguchi S: Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas. J Neurooncol. 145:201–210. 2019. View Article : Google Scholar : PubMed/NCBI
41	Zhang JG, Xu C, Zhang L, Zhu W, Shen H and Deng HW: Identify gene expression pattern change at transcriptional and post-transcriptional levels. Transcription. 10:137–146. 2019. View Article : Google Scholar : PubMed/NCBI
42	Martin J, Herbert B and Hocevar B: Disabled-2 downregulation promotes epithelial-to-mesenchymal transition. Br J Cancer. 103:1716–1723. 2010. View Article : Google Scholar : PubMed/NCBI
43	Sun C, Yao X, Jiang Q and Sun X: miR-106b targets DAB2 to promote hepatocellular carcinoma cell proliferation and metastasis. Oncol Lett. 16:3063–3069. 2018.PubMed/NCBI
44	Yang YF, Wang YY, Hsiao M, Lo S, Chang YC, Jan YH, Lai TC, Lee YC, Hsieh YC and Yuan SF: IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway. Cancer Lett. 485:27–37. 2020. View Article : Google Scholar : PubMed/NCBI
45	He K, Guo X, Liu Y, Li J, Hu Y, Wang D and Song J: TUFM downregulation induces epithelial-mesenchymal transition and invasion in lung cancer cells via a mechanism involving AMPK-GSK3β signaling. Cell Mol Life Sci. 73:2105–2121. 2016. View Article : Google Scholar : PubMed/NCBI
46	Han SY, Jeong YJ, Choi Y, Hwang SK, Bae YS and Chang YC: Mitochondrial dysfunction induces the invasive phenotype, and cell migration and invasion, through the induction of AKT and AMPK pathways in lung cancer cells. Int J Mol Med. 42:1644–1652. 2018.PubMed/NCBI
47	Wu SB, Wu YT, Wu TP and Wei YH: Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochim Biophys Acta. 1840:1331–1344. 2014. View Article : Google Scholar : PubMed/NCBI
48	Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA and Lawler SE: MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell. 37:620–632. 2010. View Article : Google Scholar : PubMed/NCBI
49	Gongol B, Sari I, Bryant T, Rosete G and Marin T: AMPK: An epigenetic landscape modulator. Int J Mol Sci. 19:32382018. View Article : Google Scholar : PubMed/NCBI